Peru is a high-potential medical device market in South America, regulated by DIGEMID under a four-tier risk classification system aligned with IMDRF. Unlike Colombia and Mexico, Peru offers no simplified equivalence pathway; full technical review applies to all risk classes, yet its official registration fees are the lowest among the three jurisdictions. Based on the takeaways shared at the Beijing CMEF open class, this article outlines applicable regulations, classification rules, registration pathways, documentation, change control and vigilance requirements to deliver practical reference for overseas manufacturers.
Governing Authority: DIGEMID (General Directorate of Medicines, Medical Devices and Health Products), subordinate to MINSA (Ministry of Health). The DDMP Medical Devices Division conducts technical reviews.
Primary Legislation: Ley 29459 (Law of Medicines, Medical Devices and Health Products)
Core Implementing Rules: DS-016-2011-SA (registration administration); DS-003-2020-SA (risk classification rules); DS-014-2011-SA (establishment administration)
Registration Certificate: Resolución Directoral (Sanitary Registration Certificate), valid for 5 years, submitted electronically through the VUCE system.
| Risk Class | Risk Description | Review Timeline | Examples |
|---|---|---|---|
| Class I | Low risk, non-invasive, contact with intact skin | 22 working days | General gloves, face masks, tongue depressors |
| Class II | Medium risk, contact with mucous membranes / short-term invasion (<30 days) | 22 working days | Syringes, catheters, condoms |
| Class III | High risk, long-term invasion, energy-emitting devices | 66 working days | Ventilators, anaesthesia machines, surgical lasers |
| Class IV | Very high risk, implanted devices, blood contact, central nervous system contact; drug-combination devices | 66 working days | Heart stents, pacemakers, blood screening IVDs, drug-coated catheters |
Key Rules: Devices with auxiliary medicinal components are directly classified as Class IV. Standalone SaMD starts at Class II; software supporting therapeutic decision-making is upgraded to Class III–IV. Peru has no RELIANCE-style equivalence pathway; a full review is mandatory for all products.
Exceptional Import (Autorización Excepcional):For unregistered products, compassionate clinical use may apply for temporary import. Compassionate use for individual patients can be cleared in as fast as 1 working day.
The Certificate Holder (Titular) must be a local Peruvian Droguería (import/distribution entity) or Laboratorio (manufacturer). Foreign manufacturers cannot hold the registration certificate directly.
Premises must hold an Autorización Sanitaria (Sanitary Operating Licence). Droguería importers must comply with BPA warehousing standards; manufacturing sites are subject to on-site inspection against BMP manufacturing standards.
Mandatory appointment of a Químico-Farmacéutico (Pharmaceutical Technical Responsible Person) holding a local practising licence and registered in the DIGEMID system.
Quality System: ISO 13485, CE and FDA certificates are accepted. For high-risk Class IV devices, FSC and ISO certificates must be issued within the preceding 12 months.
Labels and instructions for use must be in Spanish. Free Sale Certificate (CLC) requires Hague Apostille authentication.
Submission format:Electronic filing via VUCE + hard copy + non-rewritable CD-ROM.
Transfer of registration rights also requires official DIGEMID approval.
Fatal serious adverse events: Urgent notification within 24 hours, full technical report supplementary submission within 10 calendar days via the NotiMED platform.
Class III / IV high-risk devices require periodic safety update reports. Regulators may conduct market sampling and on-site warehouse inspections. Enterprises shall proactively implement product recalls.
| Risk Class | New Registration Fee |
|---|---|
| Class I | S/ 1,348.50 (approx. CNY 2,700) |
| Class II | S/ 1,558.50 |
| Class III | S/ 1,811.10 |
| Class IV | S/ 2,051.00 |